References in periodicals archive ?
This study forecasts the future of the leading five classes of antibacterial drug, as well as the top 20 individual drugs, showing revenue forecasts to 2022.
com has added a new market research report: Antibacterial Drugs Market (By Class and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 http://www.
Nevertheless, the growing threat posed by antibacterial drug resistance is all too real.
The work also discusses these aspects of the antibacterials field: -- Opportunities for biotechs, including developing of biological drug therapies -- Genomics in antibacterial drug development -- Public funding for research and antibiotic development -- Concerns over safety and marketing -- Oxazolidinone product launches with potential to invigorate the market -- Activity against MRSA stimulating revenue growth.
The topics include the impact of microbial natural products on antibacterial drug discovery, the membrane as a novel target site for antibiotics to kill persisting bacterial pathogens, recent developments in inhibitors of bacterial type IIA topoisomerases, antibiotics targeting translation initiation in prokaryotes, and selected structural aspects of antibiotics at the ribosomal exit tunnel.
In a series of laboratory experiments, the researchers have shown that it is possible to kill Mycobacterium tuberculosis by inhibiting ClpP, a cellular enzyme that is not targeted by any antibacterial drug on the market.
Those findings appear in Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022, published in June 2012.
FDA approval of polymyxin B for injection, USP, an antibacterial drug, in 500,000 units per vial, latex-free glass vials.
Even a suspected peripheral ulcer of this type should be considered for antibacterial drug treatment, even if just for prophylaxis (see later).
San Diego-based Trius Therapeutics has closed a $30 million Series B financing to advance the clinical development of its best-in-class oxazolidinone antibacterial drug TR-701, now completing Phase I testing.
To our knowledge, previous population-based surveys have not assessed misconceptions about antibacterial drug use over time.
The objective is to develop an antibacterial drug that will fight a broad spectrum of pathogens, including E.
Though we are currently concentrating our technology on antibacterial drug discovery, the assay is amenable to numerous potential targets of drugs that are relevant to many human, veterinary, and agricultural diseases.
The various classes of antibacterial drug included in this report are beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, folate antagonists, tetracyclines, and other miscellaneous agents, which include glycopeptides, nitroimidazoles, lincosamides, lipopeptides, nicotinic acid derivatives, and polypeptide antibiotics.